The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Apr 24, 2023
Trial Information
Current as of June 18, 2025
Recruiting
Keywords
ClinConnect Summary
The STEREO-DBS Study is looking at how advanced imaging technology, specifically 7-Tesla MRI, can help improve deep brain stimulation (DBS) for people with advanced Parkinson's disease. This study aims to see if using this high-resolution imaging can better guide the placement of DBS electrodes, which may lead to greater improvements in motor symptoms for patients. Currently, about half of patients do not experience enough benefit from DBS, and this research could help change that by allowing doctors to see important connections in the brain that traditional imaging methods miss.
To be eligible for this study, participants need to be over 18 years old and have Parkinson's disease that has not responded well to standard treatments. They will not need to undergo any additional procedures since the use of 7-Tesla MRI is part of regular care. Throughout the study, participants can expect to have their motor symptoms evaluated, as well as their daily functioning and quality of life, after six months of treatment. The study is currently recruiting participants, and involvement poses very little risk, as it involves standard care practices already in place.
Gender
ALL
Eligibility criteria
- • 1.2 Inclusion criteria
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- • Age \> 18 years;
- • Idiopathic PD who underwent STN DBS
- • 1.3 Exclusion criteria
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- • Legally incompetent adults;
- • No written informed consent.
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Maarten Bot, MD PhD
Principal Investigator
Amsterdam UMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported